Lipella Pharmaceuticals Initiates Phase 2a Trial for LP-310 in Oral Lichen Planus, Enrolls First Patients
Lipella Pharmaceuticals (Nasdaq: LIPO) has initiated a Phase 2a clinical trial for LP-310, enrolling the first patients to evaluate its efficacy in treating Oral Lichen Planus (OLP). This chronic inflammatory condition affects over 6 million Americans and currently lacks FDA-approved treatments. The multi-center, dose-ranging study is testing LP-310, a proprietary liposomal-tacrolimus oral rinse formulation derived from Lipella's lead candidate LP-10 for hemorrhagic cystitis.
The trial has commenced across multiple research sites nationwide, from Philadelphia to San Francisco. Lipella expects to conclude the trial by mid-2025, with top-line data anticipated by year-end 2024. LP-310 aims to address the underlying causes of OLP, potentially offering a transformative therapy that could alleviate symptoms and improve patient outcomes while minimizing systemic toxicity.
Lipella Pharmaceuticals (Nasdaq: LIPO) ha avviato uno studio clinico di fase 2a per LP-310, reclutando i primi pazienti per valutare la sua efficacia nel trattamento del Lichen Planus orale (OLP). Questa condizione infiammatoria cronica colpisce oltre 6 milioni di americani e attualmente non dispone di trattamenti approvati dalla FDA. Lo studio multicentrico e dose-rispondente sta testando LP-310, una formulazione di risciacquo orale a base di tacrolimus liposomiale, derivata dal principale candidato di Lipella, LP-10, per la cistite emorragica.
Lo studio è iniziato in diversi centri di ricerca in tutto il paese, da Filadelfia a San Francisco. Lipella prevede di concludere lo studio entro la metà del 2025, con dati preliminari attesi entro la fine del 2024. LP-310 mira a affrontare le cause sottostanti dell'OLP, offrendo potenzialmente una terapia trasformativa che potrebbe alleviare i sintomi e migliorare i risultati dei pazienti, riducendo al contempo la tossicità sistemica.
Lipella Pharmaceuticals (Nasdaq: LIPO) ha iniciado un ensayo clínico de fase 2a para LP-310, reclutando a los primeros pacientes para evaluar su eficacia en el tratamiento del Líquen plano oral (OLP). Esta condición inflamatoria crónica afecta a más de 6 millones de estadounidenses y actualmente no tiene tratamientos aprobados por la FDA. El estudio multicéntrico y de rango de dosis está probando LP-310, una formulación de enjuague bucal de tacrolimus liposomal, derivada del candidato principal de Lipella, LP-10, para la cistitis hemorrágica.
El ensayo ha comenzado en múltiples sitios de investigación en todo el país, desde Filadelfia hasta San Francisco. Lipella espera concluir el ensayo a mediados de 2025, con datos preliminares anticipados para finales de 2024. LP-310 tiene como objetivo abordar las causas subyacentes del OLP, ofreciendo potencialmente una terapia transformadora que podría aliviar los síntomas y mejorar los resultados de los pacientes, mientras minimiza la toxicidad sistémica.
리펠라 제약회사(Lipella Pharmaceuticals, Nasdaq: LIPO)가 LP-310의 2a상 임상 시험을 시작하며 첫 환자를 등록하여 구강 백선증(OLP) 치료의 효능을 평가하고 있습니다. 이 만성 염증 질환은 600만 이상의 미국인에게 영향을 미치며, 현재 FDA 승인 치료법이 없습니다. 이 다기관, 용량 범위 연구는 출혈성 방광염에 대한 리펠라의 주요 후보물질 LP-10을 기반으로 한 독점적 리포솜 타크롤리무스 구강 세척제인 LP-310을 시험하고 있습니다.
시험은 필라델피아에서 샌프란시스코까지 미국 전역의 여러 연구 사이트에서 시작되었습니다. 리펠라는 2025년 중반까지 시험을 마감할 것으로 예상하며, 2024년 연말까지 주요 데이터를 예상하고 있습니다. LP-310은 OLP의 근본 원인을 처리하는 것을 목표로 하며, 잠재적으로 증상을 완화하고 환자 결과를 개선하면서 전신 독성을 최소화하는 혁신적인 치료를 제공할 수 있습니다.
Lipella Pharmaceuticals (Nasdaq: LIPO) a lancé un essai clinique de phase 2a pour LP-310, recrutant les premiers patients afin d'évaluer son efficacité dans le traitement du lichen plan oral (OLP). Cette condition inflammatoire chronique touche plus de 6 millions d'Américains et ne dispose actuellement d'aucun traitement approuvé par la FDA. L'étude multicentrique et à dose variable teste le LP-310, une formulation de rinçage buccal à base de tacrolimus liposomal, dérivée du principal candidat de Lipella, LP-10, pour la cystite hémorragique.
L'essai a commencé dans plusieurs sites de recherche à travers le pays, de Philadelphie à San Francisco. Lipella prévoit de conclure l'essai d'ici la mi-2025, avec des données préliminaires attendues d'ici la fin de l'année 2024. LP-310 vise à traiter les causes sous-jacentes de l'OLP, offrant ainsi potentiellement une thérapie transformative qui pourrait soulager les symptômes et améliorer les résultats pour les patients tout en minimisant la toxicité systémique.
Lipella Pharmaceuticals (Nasdaq: LIPO) hat eine klinische Phase-2a-Studie für LP-310 gestartet und die ersten Patienten rekrutiert, um die Wirksamkeit bei der Behandlung von orchal Lichen Planus (OLP) zu bewerten. Diese chronische entzündliche Erkrankung betrifft über 6 Millionen Amerikaner und hat derzeit keine von der FDA zugelassenen Behandlungen. Die multizentrische, dosisabhängige Studie testet LP-310, eine proprietäre liposomale Tacrolimus-Mundspülung, die aus Lipellas Hauptkandidaten LP-10 für hämorrhagische Zystitis abgeleitet ist.
Die Studie hat an mehreren Forschungsstandorten im ganzen Land begonnen, von Philadelphia bis San Francisco. Lipella erwartet, die Studie bis Mitte 2025 abzuschließen, mit Top-Line-Daten, die bis Ende 2024 erwartet werden. LP-310 zielt darauf ab, die zugrunde liegenden Ursachen von OLP zu behandeln und könnte potenziell eine transformative Therapie bieten, die Symptome lindern und die Ergebnisse der Patienten verbessern kann, während sie gleichzeitig die systemische Toxizität minimiert.
- Initiation of Phase 2a clinical trial for LP-310 in Oral Lichen Planus
- Successful enrollment of first patients across multiple research sites
- Potential to address a market of over 6 million affected Americans
- LP-310 targets underlying causes of OLP, aiming to minimize systemic toxicity
- Top-line data expected by year-end 2024
- None.
Insights
Lipella Pharmaceuticals' initiation of a Phase 2a trial for LP-310 in Oral Lichen Planus (OLP) represents a significant step forward in addressing an unmet medical need. With over 6 million Americans affected by OLP, the lack of FDA-approved treatments underscores the importance of this clinical trial.
The multi-center, dose-ranging study design is a standard approach for Phase 2a trials, allowing researchers to evaluate both efficacy and optimal dosing. The enrollment of the first patients across multiple sites nationwide indicates strong interest from both clinicians and patients, which bodes well for recruitment efforts.
LP-310's innovative formulation as a liposomal-tacrolimus oral rinse is particularly noteworthy. This approach aims to deliver a high local concentration of the drug while minimizing systemic exposure, potentially offering a better safety profile compared to systemic immunosuppressants. The repurposing of tacrolimus, an established immunosuppressant, for topical use in OLP is a clever strategy that could expedite the development process.
The expected conclusion of the trial by mid-2025, with top-line data anticipated by year-end 2024, suggests a well-planned timeline. However, investors should be aware that clinical trials often face delays and these timelines should be viewed as estimates.
While the potential market for an effective OLP treatment is substantial, it's important to remember that Phase 2a trials primarily focus on safety and early efficacy signals. Success here would be promising, but further studies would be required before potential FDA approval.
The initiation of Lipella Pharmaceuticals' Phase 2a trial for LP-310 is a positive development for the company, potentially expanding its pipeline beyond its lead candidate LP-10 for hemorrhagic cystitis. This diversification could enhance Lipella's value proposition to investors.
However, it's important to note that as a clinical-stage biotech company, Lipella's financial performance will likely be driven more by clinical milestones than immediate revenue. The company's ability to fund this trial and potential future studies will be crucial. Investors should closely monitor Lipella's cash burn rate and financing strategies.
The OLP market, with over 6 million affected Americans, represents a significant commercial opportunity if LP-310 proves successful. The lack of FDA-approved treatments suggests potential for premium pricing and rapid market penetration upon approval. However, this is contingent on positive trial results and successful navigation of the regulatory process.
The expected timeline for top-line data by year-end 2024 provides a clear catalyst for potential stock movement. Positive results could drive significant upside, while negative outcomes might lead to a sharp decline, given the company's likely dependence on clinical success for valuation.
Investors should also consider the broader competitive landscape in OLP treatment development and Lipella's intellectual property position for LP-310. These factors will be critical in determining the long-term commercial potential of the drug, should it reach the market.
Top Line Data Expected Year-End 2024
PITTSBURGH, July 29, 2024 (GLOBE NEWSWIRE) -- Lipella Pharmaceuticals Inc. (Nasdaq: LIPO) (“Lipella” or the “Company”), a clinical-stage biotechnology company addressing serious diseases with significant unmet need, today announced the enrollment of the first patients in its multi-center Phase 2a clinical trial evaluating LP-310 for the treatment of Oral Lichen Planus (OLP). This chronic inflammatory condition, which affects over 6 million Americans, is characterized by mouth mucous membrane inflammation, pain, and ulceration, and lacks FDA-approved treatments.
Lipella's Phase 2a trial is a multi-center, dose-ranging study of LP-310, a proprietary liposomal-tacrolimus oral rinse formulation of the company’s lead candidate LP-10 for hemorrhagic cystitis. The trial has enrolled its first patients across multiple research sites nationwide, spanning from Philadelphia to San Francisco, and is actively screening additional subjects with symptomatic Oral Lichen Planus.
Dr. Jonathan Kaufman, CEO of Lipella Pharmaceuticals, commented, "We are very pleased with the rapid pace of site activation, and the enrollment of our initial patients marks a pivotal milestone for both the company and the patient community suffering from this debilitating condition. This achievement reinforces our mission to redefine treatment paradigms for Oral Lichen Planus. With LP-310’s innovative approach to targeting disease mechanisms, we are excited about the potential to deliver a transformative therapy, alleviating symptoms and improving patient outcomes significantly."
LP-310 is designed to address the underlying causes of OLP, offering a promising alternative to current palliative treatments and delivering local concentration in the oral cavity, aiming to minimize systemic toxicity. The trial is anticipated to conclude by mid-2025, with top-line data expected year-end 2024.
Dr. Michael Chancellor, Chief Medical Officer of Lipella added, “We have heard the urgency for new effective OLP therapies from patients, clinicians and advocacy groups. OLP not only induces debilitating physical symptoms but also poses risks of serious complications. LP-310's potential to mitigate these challenges represents a significant advancement in therapeutic options."
For more information on the clinical trial, please visit: https://lipella.com/lp-310-oral-lichen-planus/. Additionally, news about the trial is being shared on Facebook OLP support groups, and patients are reaching out with questions.
About Oral Lichen Planus
Oral Lichen Planus (OLP) is a serious and debilitating condition characterized by oral mucosal lesions. It affects millions of individuals worldwide and presents significant challenges in terms of management and treatment. Current therapeutic options are limited, underscoring the critical need for innovative approaches like LP-310 in addressing this unmet medical need.
About Lipella Pharmaceuticals
Lipella is a clinical-stage biotechnology company focused on developing new drugs by reformulating the active agents in existing generic drugs and optimizing these reformulations for new applications. Additionally, Lipella maintains a therapeutic focus on diseases with significant, unaddressed morbidity and mortality where no approved drug therapy currently exists. Lipella completed its initial public offering in December 2022. For more information, please visit www.lipella.com or LinkedIn.
Forward-Looking Statements
This press release includes certain “forward-looking statements.” All statements, other than statements of historical fact, included in this press release regarding, among other things, our strategy, future operations, financial position, prospects, pipeline and opportunities, sources of growth, successful implementation of our proprietary technology, plans and objectives are forward-looking statements. Forward-looking statements can be identified by words such as “may,” “will,” “could,” “continue,” “would,” “should,” “potential,” “target,” “goal,” “anticipates,” “intends,” “plans,” “seeks,” “believes,” “estimates,” “predicts,” “expects,” “projects” and similar references to future periods. Forward-looking statements are based on our current expectations and assumptions regarding future events and financial trends that we believe may affect among other things, our financial condition, results of operations, business strategy, short- and long-term business operations and objectives, and financial needs. Because forward-looking statements relate to the future, they are subject to inherent uncertainties, risks and changes in circumstances that are difficult to predict. Our actual results may differ materially from those contemplated by the forward-looking statements. We caution you, therefore, against relying on any of these forward-looking statements. They are neither statements of historical fact nor guarantees or assurances of future performance. There are risks, uncertainties and other factors, both known and unknown, that could cause actual results to differ materially from those in the forward-looking statements which include, but are not limited to, regional, national or global political, economic, business, competitive, market and regulatory conditions, and other factors. Any forward-looking statement made by us is based upon the reasonable judgment of our management at the time such statement is made and speaks only as of the date on which it is made. Factors or events that could cause our actual results to differ may emerge from time to time, and it is not possible for us to predict all of them. We undertake no obligation to update any forward-looking statement, whether as a result of new information, future developments or otherwise, except as may be required by applicable law. Nothing contained herein is, or shall be relied upon as, a promise or representation as to the past or future. In addition, the information contained in this press release is as of the date hereof, and the Company has no obligation to update such information, including in the event that such information becomes inaccurate. You should not construe the contents of this press release as legal, tax and financial advisors as to legal and related matters concerning the matters described herein.
CONTACT
Dr. Jonathan Kaufman, CEO
Lipella Pharmaceuticals
Info@Lipella.com
1-412-894-1853
Jeff Ramson
PCG Advisory
jramson@pcgadvisory.com
646-863-6893
FAQ
What is the purpose of Lipella Pharmaceuticals' Phase 2a trial for LP-310?
When does Lipella Pharmaceuticals (LIPO) expect top-line data from the LP-310 Phase 2a trial?
How many Americans are affected by Oral Lichen Planus, the condition targeted by Lipella's LP-310?
What is unique about Lipella Pharmaceuticals' LP-310 treatment for Oral Lichen Planus?
